Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Diane Gomez-Thinnes as its new chief commercial officer (CCO). Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, […]
Better Therapeutics
Published data backs digital therapeutic for diabetes from Better Therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that newly published data supports its digital therapeutic for type 2 diabetes. San Francisco-based Better Therapeutics develops the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. In July, the company completed the pivotal trial for its BT-001 digital therapeutic […]
7 innovative digital health offerings to treat diabetes
From using your smartphone to track data to reversing your diabetes altogether, these digital health technologies stand out. Advances in treatments for diabetes never stop coming. Whether that be in the form of insulin pumps or continuous glucose monitors, we’ve seen plenty. Moving away from the physical device, innovations in the digital diabetes space continue […]
Better Therapeutics submits FDA de novo request for type 2 diabetes treatment
Better Therapeutics (Nasdaq:BTTX) announced today that it submitted a de novo classification request to the FDA for its BT-001 technology. San Francisco-based Better Therapeutics seeks marketing authorization for the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. Marketing initially would cover type […]
Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
Better Therapeutics (Nasdaq:BTTX) posted second-quarter quarter results today that beat the consensus forecast on Wall Street as it prepared to submit its first product for FDA review. Better Therapeutics has not yet generated revenue from the commercialization or sale of any product. The company went public through a special purpose acquisition company merger in October. […]
Better Therapeutics completes trial for type 2 diabetes treatment, will submit to FDA
Better Therapeutics (Nasdaq:BTTX) announced today that it completed the pivotal trial for its BT-001 digital therapeutic for diabetes. San Francisco-based Better Therapeutics designed its nutritional cognitive behavioral therapy (nCBT) platform to address the root causes of cardiometabolic diseases. It designed its investigational, first-in-class BT-001 prescription digital therapeutic (PDT) to use nCBT to treat type 2 […]
Digital therapeutics developer Better Therapeutics names new CEO
Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Frank Karbe as its new president and CEO. San Francisco-based Better Therapeutics develops prescription digital therapeutics (PDTs) based on nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases. Karbe will join the company as president and CEO and will serve as a member […]
Digital therapeutics open up new opportunities in medicine
A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]
Better Therapeutics reaches key milestones for prescription digital therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that it hit multiple key research milestones as it validates its digital therapeutics. San Francisco-based Better Therapeutics develops prescription digital therapeutics designed to deliver a novel form of cognitive-behavioral therapy for treating cardiometabolic diseases, potentially improving key measures related to type 2 diabetes, hypertension and more. Better Therapeutics’ platform aims […]
Better Therapeutics completes enrollment in type 2 diabetes study
Better Therapeutics (NSDQ:BTTX) announced that it completed patient enrollment in a study of its digital therapeutic in treating diabetes. San Francisco-based Better Therapeutics’ BT-001 prescription digital therapeutic delivers a novel cognitive-behavioral therapy to patients with uncontrolled type 2 diabetes. According to a news release, the trial for BT-001 exceeded its enrollment target, bringing in 662 […]
